• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Report: A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection

tetano

Editor, Senior Moderator
[h=1]A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection[/h] Mukta Dutta[SUP]5[/SUP]
, Shelly J. Robertson[SUP]5[/SUP]
, Atsushi Okumura
, Dana P. Scott
, Jean Chang
, Jeffrey M. Weiss
, Gail L. Sturdevant
, Friederike Feldmann
, Elaine Haddock
, Abhilash I. Chiramel
, Sanket S. Ponia
, Jonathan D. Dougherty
, Michael G. Katze
, Angela L. Rasmussen
, Sonja M. Best[SUP]6[/SUP][SUP],[/SUP]
article_notepad.gif
Press enter key for correspondence informationPress enter key to Email the author
[SUP]5[/SUP]Co-first author
[SUP]6[/SUP]Lead Contact
[h=2]Highlights[/h]
  • ? MAVS determines early differences in replication between WT and MA Ebola virus in mice
  • ? MAVS controls expression of IFN-I, inflammatory responses, and cell death
  • ? MAVS signaling specifically in myeloid cells is required for control of EBOV replication
  • ? MAVS has both IFN-I-dependent and -independent roles in the control of EBOV


[h=2]Summary[/h] The unprecedented 2013?2016 outbreak of Ebola virus (EBOV) resulted in over 11,300 human deaths. Host resistance to RNA viruses requires RIG-I-like receptor (RLR) signaling through the adaptor protein, mitochondrial antiviral signaling protein (MAVS), but the role of RLR-MAVS in orchestrating anti-EBOV responses in vivo is not known. Here we apply a systems approach to MAVS[SUP]−/−[/SUP] mice infected with either wild-type or mouse-adapted EBOV. MAVS controlled EBOV replication through the expression of IFNα, regulation of inflammatory responses in the spleen, and prevention of cell death in the liver, with macrophages implicated as a major cell type influencing host resistance. A dominant role for RLR signaling in macrophages was confirmed following conditional MAVS deletion in LysM+ myeloid cells. These findings reveal tissue-specific MAVS-dependent transcriptional pathways associated with resistance to EBOV, and they demonstrate that EBOV adaptation to cause disease in mice involves changes in two distinct events, RLR-MAVS antagonism and suppression of RLR-independent IFN-I responses.

full article

http://www.cell.com/cell-reports/fulltext/S2211-1247(16)31776-4
 
Back
Top